US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Medincell

34.39

0.0000

Volume:- -

Turnover:- -

Market Cap:1.14B

PE:-46.27

High:34.39

Open:34.39

Low:34.39

Close:34.39

52wk High:34.39

52wk Low:6.98

Shares:33.10M

Float Shares:20.90M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7432

EPS(LYR):-0.6725

ROE:540.19%

ROA:-9.16%

PB:-31.45

PE(LYR):-51.14

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: Medincell - UZEDY(R): Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)

Press Release: Medincell: Publication of the 2026 Financial Calendar

Press Release: Medincell Publishes its Consolidated Half-Year Financial Results

Press Release: Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MDCLF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCLF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCLF\",,,,,undefined,":{"symbol":"MDCLF","market":"US","secType":"STK","nameCN":"Medincell","latestPrice":34.39,"timestamp":1770411600000,"preClose":34.39,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":20901284,"shares":33102886,"eps":-0.743243,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 16:00:00 EST Delay","open":34.39,"high":34.39,"low":34.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.743243,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"exchange":"EXPERT","adjPreClose":34.39,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCLF\",,,,,undefined,":{"symbol":"MDCLF","floatShares":20901284,"roa":"-9.16%","roe":"540.19%","lyrEps":-0.672465,"shares":33102886,"dividePrice":0,"high":34.39,"amplitude":0,"preClose":34.39,"low":34.39,"week52Low":6.9757,"pbRate":"-31.45","psRate":"29.70","week52High":34.39,"institutionHeld":0,"latestPrice":34.39,"eps":-0.743243,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.743243,"open":34.39,"prevYearClose":6.9757,"prevWeekClose":34.39,"prevMonthClose":34.39,"prevQuarterClose":6.9757},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCLF\",params:#limit:5,,,undefined,":[{"date":"2022-06-14","symbol":"MDCLF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1655193600000,"name":null,"time":"","dateTimestamp":1655179200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCLF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCLF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1765429200000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCLF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606711859","title":"Press Release: Medincell - UZEDY(R): Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606711859","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606711859?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:04","pubTimestamp":1769605440,"startTime":"0","endTime":"0","summary":"Medincell's  partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and full--year 2025 results:. --  2025 net sales reached $191 million, including $55 million in the. --  Teva's initial 2026 net sales outlook is in the range of $250 - $280. Medincell receives mid--to high--single-digit royalties on UZEDY net sales and is eligible for up to $105 million in commercial milestone payments, subject to the achievement of annual sales thresholds.Olanzapine Long-Acting Injectable  has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation for a broad population of patients living with schizophrenia.Medincell is eligible to receive mid--to high--single-digit royalties on all sales, a $4 million payment upon approval, and for up to $105 million in commercial milestone payments, subject to the achievement of annual sales thresholds.Teva Q4 2025 earnings conference call today at 8:00am ET, webcast ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCLF","R"],"gpt_icon":0},{"id":"2603542736","title":"Press Release: Medincell: Publication of the 2026 Financial Calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2603542736","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603542736?lang=en_us&edition=fundamental","pubTime":"2026-01-13 01:00","pubTimestamp":1768237200,"startTime":"0","endTime":"0","summary":"Risperidone LAI was the first treatment based on BEPO technology to receive FDA approval, initially for schizophrenia in April 2023, and subsequently for Bipolar I Disorder in October 2025. It is marketed in the United States by Teva under the brand name UZEDY . Medincell's risperidone LAI was also approved for schizophrenia in Canada and South Korea in 2025.Medincell's investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options.Headquartered in Montpellier, France, Medincell employs over 140 people representing more than 25 nationalities.This press release may contain forward-looking statements, particularly concerning the progress of the Company's clinical trials. Although the Company considers that its forecasts are based on reasonable assumptions, any statements oth","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4588","BK4232","BK4099","BK4007","BK4555","BK4604","MDCLF","TM","BK4585","03160","R"],"gpt_icon":0},{"id":"2590323668","title":"Press Release: Medincell Publishes its Consolidated Half-Year Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2590323668","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590323668?lang=en_us&edition=fundamental","pubTime":"2025-12-10 01:02","pubTimestamp":1765299720,"startTime":"0","endTime":"0","summary":"Christophe Douat, CEO of Medincell : \"We are pleased with the company's growth and momentum. We have entered the most transformative years in Medincell's history. UZEDY delivers strong performance and the expected launch of olanzapine LAI next year is poised to be a major catalyst for Medincell's growth. We keep advancing the third engine of our Shift to Growth strategy, with our first program in partnership with AbbVie leading the way, while further expanding and diversifying our pipeline and collaborations with leading pharmaceutical partners.\". Stéphane Postic, CFO of Medincell: \"Revenues are growing and are expected to accelerate in the coming years with Olanzapine LAI. We have refined our investment plan to allocate resources strategically, with discipline and ambition. This approach is designed to create sustainable value and position Medincell for long-term success.\". Consolidated financial statements for the first half of the 2025-2026 fiscal year, ending September 30, 2025 . -","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","MDCLF","BK4115","AIC","R","BK4022","CNSL","BK4007"],"gpt_icon":0},{"id":"2588774920","title":"Press Release: Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588774920","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588774920?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:00","pubTimestamp":1764608400,"startTime":"0","endTime":"0","summary":"Medincell  will hold a videoconference on Tuesday December 9, 2025 to present the half-year financial results . Shareholders are invited to send their questions to communication@medincell.com, or through the chat system during the videoconference.Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.These treatments combine active pharmaceutical ingredients with our proprietary BEPO technology, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable deposit.Headquartered in Montpellier, France, Medincell employs over 140 people representing more than 25 nationalities.These statements may ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","TM","BK4555","03160","MDCLF","BK4585","BK4007","CET","BK4588","BK4022","BK4099","R","BK4232"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MDCLF\",params:#limit:6,delay:false,,,undefined,":[]}}